1. Introduction: The introduction of a variety of radiopharmaceuticals for the internal therapy of malignant or inflammatory lesions during the past decade has been a notable feature. The use of certain bone seeking radiopharmaceuticals is becoming increasingly popular because their use tends to relieve the metastatic bone pain without the undesirable side effects associated with narcotics. Several compounds of radionuclides like ~89Sr, ~188Re, ~153Sm, ~166Ho, ~90Y, ~32P etc are currently used in palliation therapy [1]. The choice of a radionuclide for therapeutic applications is governed by various factors such as the characteristics of radiations emitted (type and energy of radiation), half-life, specific activity, ease of production, natural abundance of target nuclide, radionuclide purity and the feasibility of producing the radionuclide in a suitable form for application. Pure beta-emitting radionuclides are often preferred for use in clinical radionuclide therapy (RNT), while the merits of accompanying gamma emissions in low abundance to facilitate imaging and dosimetry are notable as well described in literature [2].
展开▼
